MergerMay 4, 2026, 09:17 AM
Gyre Therapeutics Completes $300M All-Stock Merger with Cullgen
AI Summary
Gyre Therapeutics, Inc. announced the completion of its previously announced all-stock acquisition of Cullgen Inc., valued at approximately $300 million. Cullgen now operates as a wholly owned subsidiary of Gyre, creating a U.S.- and China-based fully integrated biopharmaceutical company. The combined entity boasts a revenue-producing commercial asset, ETUARY®, and a robust pipeline of products and candidates, including targeted protein degraders and degrader-antibody conjugates. Dr. Ying Luo, former CEO of Cullgen, has been appointed President and CEO of Gyre, which will continue to trade on Nasdaq under the ticker "GYRE".
Key Highlights
- Gyre Therapeutics completed the acquisition of Cullgen Inc. in an all-stock transaction.
- The acquisition valued Cullgen at approximately $300 million.
- Cullgen became a wholly owned subsidiary of Gyre Therapeutics.
- Dr. Ying Luo, former Cullgen CEO, was appointed President and CEO of Gyre Therapeutics.
- The combined company has a revenue-producing commercial asset, ETUARY®, and a pipeline from discovery to Phase 3.
- Gyre will convene a stockholder meeting on June 10, 2026, for the Conversion Proposal.
- The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
- The transaction is accounted for as a combination of entities under common control by GNI Group Ltd.
Price Impact
More from GYRE